Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS4028404 A
Publication typeGrant
Application numberUS 05/464,381
Publication dateJun 7, 1977
Filing dateApr 26, 1974
Priority dateJul 31, 1967
Publication number05464381, 464381, US 4028404 A, US 4028404A, US-A-4028404, US4028404 A, US4028404A
InventorsDavid Edmund Bays, Roy Vivian Foster
Original AssigneeAllen & Hanburys Limited
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Acetic acid derivatives
US 4028404 A
Abstract
Novel phenylacetic derivatives are provided of the general formula ##STR1## in which R1, R2, R3 and R4 are as defined herein, and pharmaceutically acceptable salts thereof. These have anti-inflammatory or analgetic activity. The invention also provides a process for the production of these compounds from a ketone of the structure: ##STR2## It also provides pharmaceutical compositions including phenylacetic derivatives.
Images(6)
Previous page
Next page
Claims(14)
What is claimed is:
1. A phenylacetic acid derivative of the general formula: ##STR12## in which the group R3 CO-- may only be meta or para oriented with respect to the side chain --CR1 R2 --COR4 and in which R1 and R2, which may be the same or different, are each hydrogen or alkyl containing from 1 to 6 carbon atoms, R3 is cycloalkyl containing from 3 to 9 carbon atoms, and R4 is hydroxy or lower alkoxy containing from 1 to 6 carbon atoms, or a pharmaceutically acceptable salt of said derivative in which R4 is hydroxy with an organic or inorganic base.
2. The compound of claim 1, which is (4-cyclohexanoylphenyl) acetic acid.
3. The compound of claim 1, wherein R3 is cyclobutyl.
4. The compound of claim 1, wherein R3 is cyclopentyl.
5. The compound of claim 1, wherein R3 is cyclohexyl.
6. The compound of claim 1, which is p-(cyclobutylcarbonyl)phenylacetic acid.
7. The compound of claim 1, which is p-(cyclohexylcarbonylhydratropic acid.
8. An anti-inflammatory and analgetic composition containing an anti-inflammatory effective amount or an analgetic effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier or diluent therefor.
9. The composition according to claim 8, in which the compound is (4-cyclohexylcarbonylphenyl)acetic acid.
10. The composition of claim 8, wherein R3 is cyclobutyl.
11. The composition of claim 8, wherein R3 is cyclopentyl.
12. The composition of claim 8, wherein R3 is cyclohexyl.
13. The composition according to claim 8, in which the compound is p-(cyclobutylcarbonyl)phenylacetic acid.
14. The composition according to claim 8, in which the compound is p-(cyclohexylcarbonyl)hydratropic acid.
Description

This is a continuation-in-part of our copending application Ser. No. 372,511, filed June 22, 1973, now abandoned, which is in turn a divisional of our copending application Ser. No. 747,435, filed July 27, 1968, now U.S. Pat. No. 3,828,093, both of which being hereby incorporated herein by reference thereto.

This invention relates to novel phenylacetic acid derivatives possessing anti-inflammatory, or analgetic activity and to compositions containing the same.

The present invention provides phenylacetic acid derivatives of the general formula (I): ##STR3## in which the group R3 CO-- may only be meta or para oriented with respect to the side chain-CR1 R2 COR4 and in which R1 and R2, which may be the same or different, represent a hydrogen atom or alkyl containing 1 to 6 carbon atoms, R3 represents a cycloalkyl radical containing from 3 to 9 carbon atoms, R4 is a hydroxy or lower alkoxy group containing 1 to 6 carbon atoms, and X, Y and Z are hydrogen.

This invention also provides physiologically acceptable salts of these compounds and optically active forms and racemic mixtures of the compounds which possess asymmetric carbon atoms, i.e. those compounds in which R1 and R2 represent different radicals.

A preferred group of compounds have the general formula: ##STR4## in which R3 represents cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, and R1 and R2 represent independently hydrogen or lower alkyl of 1 to 4 carbon atoms and the group R3 CO is in the m or p position to the side chain CR1 R2 COOH, with the proviso that when R3 is cyclopropyl this is in the m-position to said side chain, and salts and simple esters thereof.

Particularly preferred compounds according to the invention are:

P-(Cyclobutylcarbonyl)phenylacetic acid

M-(Cyclopropylcarbonyl)phenylacetic acid

p-(Cyclohexylcarbonyl)hydratropic acid

We have made the unexpected discovery that certain of the compounds according to the invention possess anti-inflammatory and analgetic activity of great potential utility. Thus, those compounds in which R3 represents cyclopropyl, cyclobutyl and cyclohexyl are particularly active in those tests designed to test anti-inflammatory action.

The compounds may be formulated for use in human and veterinary medicine for therapeutic purposes. The invention therefore also provides pharmaceutical compositions comprising as active ingredients compounds of the general formula (I). Such compositions may be presented for use in a conventional manner with the aid of carriers or excipients and formulatory agents as are required and with or without supplementary medicinal agents. These compositions include, for example, solid and liquid preparations for oral use, suppositories, and injections. It is most convenient to use capsules or tablets which may be prepared according to conventional methods and may be coated if desired for oral administration. Injections may be formulated with the aid of physiologically acceptable carriers and agents as solutions, suspensions or as dry products which are reconstituted before use.

The daily dose of the active ingredient is adjusted to the need of the patient and may for example be from 25 to 500 mgm per day in divided doses depending on the age, weight and condition of the patient.

The compounds of general formula (I) may be prepared from the appropriately substituted ketone of general formula (II) ##STR5## where R3, X, Y and Z have the meanings given above and R9 may be a halomethyl, acetyl or carboxyl group. These compounds may be prepared by standard routes, for example. ##STR6##

This ketone (II) in which R9 is a bromomethyl group is then reacted further, ##STR7## This nitrile may then be reacted further to give compounds according to the invention. For example, hydrolysis with a mixture of acetic acid, water, and sulphuric acid gives the acid (I, R4 ═ OH). Treatment with lower alcohols in the presence of acid catalysts gives the esters (I, R4 ═ OAlk) ##STR8## where R10 is lower alkyl.

The ketone (II) where R9 is an acetyl group may be reacted according to the Willgerodt reaction. ##STR9##

The ketone (II) where R9 is a carboxyl group may be reacted as follows: ##STR10##

The compounds of general formula (I) in which R4 is alkoxy may also be prepared from the compounds in which R4 is a hydroxy group by conventional methods of esterification, for example by reaction with an alcohol in the presence of an acid catalyst. This product may then be reacted further by conventional methods of transesterification, for example by reaction with an alcohol in the presence of a basic catalyst to give higher or substituted esters.

Compounds of general formula (I) in which R1 and R2 are alkyl may be made by reacting the compounds of formula (I) in which R4 is alkoxy with a suitable base, for example sodium hydride, and reacting the mono- or di-anion so formed with a suitable alkylating agent, for example with methyl iodide.

Salts of the compounds of general formula (I), for example when R4 is a hydroxy group, may also be made by conventional methods, for example by reaction with organic or inorganic bases in a suitable solvent.

For those compounds in which both R1 and R2 represent hydrogen then hydrolysis of the corresponding nitrile, for example with potassium hydroxide and ethyl alcohol is appropriate, as follows: ##STR11## For those compounds of the invention in which R1 is alkyl and R2 is hydrogen, the parent nitrile, prepared by procedures described above is converted into its sodio derivative, which is treated with diethyl carbonate to give the sodio derivative of the corresponding cyanoacetic ester. Treatment of the last with an alkylating agent, for example methyl iodide, gives the alkylated cyanoacetic ester, which on hydrolysis with a mixture of acetic acid and concentrated sulphuric acid affords the compounds of the invention. This reaction is shown in Scheme 1.

The following Examples illustrate the invention:

EXAMPLE 1 (4-cyclohexylcarbonylphenyl) acetic acid

α-Bromo-p-tolylcyclohexyl ketone

Cyclohexyl p-tolyl ketone (10 g.), N-bromosuccinimide (8.8 g.) and benzoyl peroxide (0.5 g.) in carbon tetrachloride (200 ml.) were heated under reflux for 6.5 hours. Succinimide was filtered off and the solvent evaporated to give an oil (17 g.) which contained 70% of the required ketone.

4-cyclohexylcarbonylphenylacetonitrile

Crude α-bromo-p-tolylcyclohexyl ketone (17 g.), sodium cyanide (3 g.), dioxan (80 ml.) and water (20 ml.) were heated under reflux for 4 hours. The mixture when cold was poured into water and extracted with ether. Evaporation of the extracts followed by chromatography on silica gave a solid (1.5 g.) which was crystallised from light petroleum (b.p. 60-80) m.p. 102-103.

(4-cyclohexylcarbonylphenyl) acetic acid

4-cyclohexylcarbonylphenylacetonitrile (1.5 g.), water (1.5 ml.), concentrated sulphuric acid (1.5 ml.) and acetic acid (1.5 ml.) were heated under reflux for 6 hours, cooled, poured into water and extracted with ether. Removal of the solvent and crystallisation from cyclohexane gave the acid, m.p. 94-95.5.

EXAMPLE 2 p-(Cyclobutylcarbonyl)phenylacetic acid

Cyclobutyl p-tolyl ketone

Cyclobutylcarbonyl chloride (23.8 g.) in dry toluene (25 ml) was added dropwise during 1 hour to a stirred suspension of anhydrous aluminium chloride (29.4 g) in dry toluene (150 ml). After stirring a further 20 minutes, the mixture was poured into iced water (1 l) and the organic layer was separated, washed with water, dried over magnesium sulphate, filtered and evaporated. The residue was distilled under reduced pressure and the fraction b.p. 79-80/0.03 mm was collected. On standing the product solidified and the solid had m.p. 32-34.

α-Bromo-p-tolyl cyclobutyl ketone

Cyclobutyl p-tolyl ketone (30 g) and N-bromosuccinimide (31 g) in carbon tetrachloride (200 ml) were irradiated and heated under reflux with a tungsten lamp for 1.5 hours, and cooled. The mixture was filtered and the filtrate was evaporated. The residue was distilled under reduced pressure and the fraction b.p. 120-125/0.015 mm was collected.

p-(Cyclobutylcarbonyl)phenylacetonitrile

α-Bromo-p-tolyl cyclobutyl ketone (18.5 g) in dimethylformamide (50 ml) was added during 35 minutes to sodium cyanide (4 g) in dimethylformamide (100 ml) which was cooled below 10 and stirred. The solution was allowed to warm to 20 during 2 hours and poured into water (1 l). The mixture was extracted with ether (3 200 ml) and the combined extracts were dried over magnesium sulphate, filtered and evaporated. The residue was extracted with light petroleum (b.p. 60-80) (7 250 ml) and the extracts were evaporated to leave an oil which partly crystallised on standing.

p-(cyclobutylcarbonyl)phenylacetic acid

p-(Cyclobutylcarbonyl)phenylacetonitrile (8.1 g) in ethanol (50 ml) was added to potassium hydroxide (6.8 g) in water (50 ml) and the mixture was heated under reflux for 5 hours and cooled. The solution was diluted with water (100 ml), washed with ether (2 100 ml), acidified to pH 1 with hydrochloric acid and extracted with ether (3 100 ml). The combined extracts were dried over magnesium sulphate, filtered and evaporated to give a brown oil. This was extracted with a hot mixture of light petroleum (b.p. 60-80) and ethyl acetate (9:1) (3 200 ml). The solid that crystallised from the extracts on cooling was collected. It had m.p. 91-92.5.

EXAMPLE 3 m-(Cyclopropylcarbonyl)phenylacetic acid

Cyclopropyl m-tolyl ketone

m-Bromotoluene (34.2 g) in dry ether (120 ml) was added dropwise to magnesium turnings (4.8 g) in dry ether (100 ml). The heat of reaction maintained the mixture to boiling under reflux during the addition and the mixture was heated under reflux for a further hour. The mixture was cooled to 0, dry cadmium chloride (19.6 g) was added and the temperature allowed to rise to 20 C. After 1 hour, cyclopropanecarbonyl chloride (20.8 g) in dry ether (50 ml) was added dropwise and the mixture was heated under reflux for 4 hours, cooled to 0 and treated with 2 N hydrochloric acid. The ether layer was separated, washed with aqueous sodium bicarbonate (3 100 ml., 8%) and with water, dried over magnesium sulphate, filtered and evaporated. The residue was distilled under reduced pressure and the fraction b.p. 86-90/0.4 mm was collected.

α-Bromo-m-tolyl cyclopropyl ketone

A stirred suspension of cyclopropyl m-tolyl ketone (16 g) and N-bromosuccinimide (17.8 g) in carbon tetrachloride (100 ml) was irradiated and heated under reflux by means of a tungsten lamp for 2 hours and cooled. The solid was filtered off and the filtrate evaporated. The residual oil was distilled under reduced pressure and the fraction distilling at 115-130/0.1 mm was collected.

m-(Cyclopropylcarbonyl)phenylacetonitrile

α-Bromo-m-tolylcyclopropyl ketone (10 g) in dry dimethylformamide (20 ml) was added dropwise during 1 hour to a stirred suspension of sodium cyanide (1.96 g) in dry dimethylformamide (40 ml). The mixture was cooled to 10 during the addition and for a further hour, then left to stand at 20 for a further 2 hours and poured onto ice (140 g). The mixture was extracted with ethyl acetate (3 60 ml) and the extracts were combined, washed with water, dried over magnesium sulphate, filtered and evaporated to give a brown oil.

m-(Cyclopropylcarbonyl)phenylacetic acid

m-(Cyclopropylcarbonyl)phenylacetonitrile (8.1 g) and potassium hydroxide (3.36 g) in water (50 ml) and ethanol (50 ml) were heated under reflux for 5 hours and cooled. The mixture was washed with chloroform (2 50 ml), acidified to pH 1 with 5N hydrochloric acid and extracted with ethyl acetate (2 75 ml). The extracts were combined, washed with water, dried over magnesium sulphate, filtered and evaporated. The residue was distilled under reduced pressure and the fraction b.p. 170/0.1 mm collected. The distilate solidified and the solid melted at 52.

EXAMPLE 4 p-(Cyclohexylcarbonyl)hydratropic acid

2-(p-Cyclohexylcarbonyl)phenyl-2-cyanopropionic acid, ethyl ester

p-(Cyclohexylcarbonyl)phenylacetonitrile (British Pat. No. 1,226,344) (2.5 g) in diethyl carbonate (13.2 g), was heated to 110-115 and stirred. Alcoholic sodium ethoxide prepared from sodium (0.275 g) and dry ethanol (5.5 ml) was added and ethanol was allowed to distill from the heated mixture. The mixture was heated to 140 and maintained at this temperature for 2 hours and cooled. Dry ether (25 ml) was added and the solid present was collected and dissolved in ethanol (35 ml). Methyl iodide (5.96 g) was added and the mixture was heated under reflux for 1 hour and evaporated. Ethyl acetate and 2N hydrochloric acid (40 ml) was added and the mixture was shaken. The ethyl acetate layer was separated, washed with water, dried over magnesium sulphate, filtered and evaporated to give a brown oil.

p-(Cyclohexylcarbonyl)hydratropic acid

2-(p-Cyclohexylcarbonyl)phenyl-2-cyanopropionic acid, ethyl ester (2.55 g, crude) was added to a mixture of concentrated sulphuric acid (5 ml), water (5 ml) and glacial acetic acid (17 ml) and the mixture was heated under reflux for 22 hours and cooled. Water (35 ml) was added and the mixture was shaken with ether (2 50 ml). The ether solution was extracted with 2N sodium hydroxide (3 50 ml) and the alkaline extract was acidified to pH2 with 5N hydrochloric acid. The acidic mixture was extracted with ether (2 75 ml) and the extracts were dried over magnesium sulphate, filtered and evaporated to yield a brown oil.

p-(Cyclohexylcarbonyl)hydratropic acid, compound with dicyclohexylamine

p-(Cyclohexylcarbonyl)hydratropic acid (1.75 g, crude) in ethyl acetate (15 ml) was treated with dicyclohexylamine (1.5 ml) in ethyl acetate (5 ml) and the mixture was evaporated. The residue was extracted with light petroleum (b.p. 60-80) (2 50 ml) and the extracts were evaporated. The residue was triturated with dry ether and the solid was collected. It had m.p. 150-151.5.

EXAMPLE 5

To prepare 10,000 tablets each containing 100 mg. of the compound of Example 1.

Mix together 1,000 g. of powdered compound of Example 1 with 750 g. of Calcium Sulphate dihydrate and sufficient of a 5% solution of low viscosity sodium carboxymethylcellulose to produce a damp cohesive mass. Granulate the damp mass by passing through a 16 mesh sieve. Dry the granules at 45-50 C. Pass the dried granules through a 20 mesh sieve and mix the sieved granules with 240 g. of maize starch and 10 g. of magnesium stearate.

Compress the lubricated granules on a suitable tablet machine using 10/32" diameter normal concave punches to produce tablets each weighing 200 mg.

EXAMPLE 6

To prepare 100,000 sugar coated tablets each containing 100 mg. of the compound of Example 1.

Mix together 10 kg. of powdered compound of Example 1 with 7.5 kg. of Calcium Sulphate dihydrate and sufficient of a 5% solution of low viscosity sodium carboxymethylcellulose to produce a damp cohesive mass. Granulate the damp mass by passing through a 16 mesh sieve. Dry the granules at 45-50 C. Pass the dried granules through a 20 mesh sieve and mix the sieved granules with 2.4 kg. of maize starch and 100 g. of magnesium stearate.

Compress the lubricated granules on a suitable tablet machine using 10/32" diameter deep concave punches.

Place the tablet cores in a coating pan of suitable size. Heat the cores to 45 C. by means of hot air and apply 200 ml. of a syrup containing 12% by weight of Acacia and 66% by weight of sucrose. Allow the tablets to roll until they are evenly coated with the syrup then dry by means of heated air. Repeat this step.

Continue the sugar coating using a syrup containing 60% by weight of sucrose and 15% by weight of calcium phosphate until the tablet cores each weigh 325 mg.

Continue coating using a syrup containing 66% by weight of sucrose and a suitable colouring agent until the tablets weight 350 mg. each. Finally polish the tablets using known techniques.

EXAMPLE 7

To prepare 100,000 enteric coated tablets each containing 100 mg. of the compound of Example 1.

Prepare the tablet cores as described in Example 6.

Rotate the tablet cores in a suitable coating pan and apply 200 ml. of a solution containing 10% by weight of polyvinylpyrrolidone 2% by weight of polyethylene glycol 6000 in 66 o.p. industrial alcohol. Dry off the solvents with cold air and repeat the operation. Apply in a similar manner a film of cellulose acetate phthalate sufficient to enable the tablets to confirm to the distintegration test for enteric coated tablets of the British Pharmacopoeia 1963 p. 1158.

The cellulose is applied in solution in suitable mixed solvents such as acetone/alcohol and may contain plasticisers such as castor oil.

When a satisfactory thickness of cellulose acetate phthalate has been applied the sugar coating procedure as outlined in example 6 is followed.

EXAMPLE 8 Capsules

To prepare 10,000 capsules each containing 50 mg.

Mix together 500 g. finely powdered and 500 g. micro-crystalline cellulose. Fill the mixed powders into No. 4 hard gelatin capsules, each capsule containing 100 mg. of the mixture.

Although Examples 5 to 8 relate to the use of the compound of Example 1 as the active ingredient, any of the compounds of formula I may be used.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3839431 *Jun 8, 1971Oct 1, 1974Squibb & Sons IncCyclopropylmethylphenylacetic acids and derivatives
GB1226344A * Title not available
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US4201870 *Oct 17, 1977May 6, 1980Lek Tovarna Farmacevtskih In Kemicnih Izdelkov, N.Sol.O.Process for the preparation of 2-(3-benzoylphenyl)-propionic acid
US4407823 *Nov 5, 1979Oct 4, 1983Schering AktiengesellschaftNovel phenylacetic acid derivatives
US4889952 *Mar 11, 1988Dec 26, 1989Nippon Petrochemical Company, Ltd.(Phenylethenyl) phenylpropionaldehyde and method for producing (benzolyphenyl) propionic acid using the same
US4968718 *Jan 25, 1988Nov 6, 1990University Of Iowa Research FoundationTopically effective, nonsteroidal drug for use in external and internal eye inflammations
US5179124 *Oct 1, 1990Jan 12, 1993University Of Iowa Research FoundationAnti-inflammatory for use in external and internal eye inflammations
US5578610 *May 31, 1995Nov 26, 1996Albany Molecular Research, Inc.Piperidine derivatives
US5581011 *May 31, 1995Dec 3, 1996Albany Molecular Research, Inc.Aromatic ketones and processes for their preparation
US5605930 *Mar 7, 1994Feb 25, 1997The United States Of America As Represented By The Department Of Health And Human ServicesCompositions and methods for treating and preventing pathologies including cancer
US5635532 *Oct 12, 1993Jun 3, 1997The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesCompositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5635533 *Jun 6, 1995Jun 3, 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethods for inducing differentiation of a cell using phenyacetic acid and derivatives
US5654333 *Jun 6, 1995Aug 5, 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethods for prevention of cancer using phenylacetic acids and derivatives thereof
US5661179 *Jun 6, 1995Aug 26, 1997The United States Of America As Represented By The Department Of Health And Human ServicesMethods for treating neoplastic conditions using phenylacetic acid and derivatives thereof
US5663412 *Aug 8, 1996Sep 2, 1997Albany Molecular Research, Inc.Aromatic ketones
US5708025 *Jun 6, 1995Jan 13, 1998The United States Of America As Represented By The Department Of Health And Human ServicesMethods for promoting wound healing
US5710178 *Jun 6, 1995Jan 20, 1998The United States Of America As Represented By The Department Of Health And Human ServicesCompositions and methods for therapy and prevention of pathologies including cancer, AIDS, and anemia
US5712307 *Jun 6, 1995Jan 27, 1998The United States Of America As Represented By The Department Of Health And Human ServicesMethods of inducing the production of hemoglobin and treating pathologies associated with abnormal hemoglobin activity using phemylacetic acids and derivatives therof
US5750703 *Feb 2, 1995May 12, 1998Albany Molecular Research, Inc.Piperidine derivatives and process for their production
US5843994 *Jun 7, 1995Dec 1, 1998The United States Of America As Represeneted By The Department Of Health And Human ServicesCompositions and methods for treating and preventing pathologies including cancer
US5852056 *Oct 12, 1994Dec 22, 1998The United States Of America As Represented By The Department Of Health And Human ServicesPhenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
US5877213 *Jun 7, 1995Mar 2, 1999The United States Of America As Represented By The Department Of Health And Human ServicesCompositions and methods for therapy and prevention of cancer, AIDS, and anemia
US5883124 *Jun 7, 1995Mar 16, 1999The United States Of America As Represented By The Department Of Health And Human ServicesCompositions and methods for treating and preventing pathologies including cancer
US5994549 *Dec 19, 1997Nov 30, 1999Albany Molecular Research, Inc.Piperidine derivatives and process for their production
US6037376 *Oct 21, 1991Mar 14, 2000The United States Of America As Represented By The Department Of Health And Human ServicesMethods for therapy of cancer
US6147216 *Jun 2, 1995Nov 14, 2000Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6153754 *Dec 21, 1995Nov 28, 2000Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6201124Dec 21, 1995Mar 13, 2001Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6242606Jul 14, 1994Jun 5, 2001Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6340761Nov 29, 2000Jan 22, 2002Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6348597Apr 4, 2001Feb 19, 2002Merrell Pharmaceuticals, Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6444824Aug 9, 2000Sep 3, 2002Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6448406Aug 9, 2000Sep 10, 2002Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6452011Aug 9, 2000Sep 17, 2002Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6458958Aug 9, 2000Oct 1, 2002Albany Molecular Research, Inc.Process for production of piperidine derivatives
US6479663Dec 1, 2000Nov 12, 2002Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6548675Dec 5, 2000Apr 15, 2003Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6552200Nov 29, 2000Apr 22, 2003Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6555689Dec 1, 2000Apr 29, 2003Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6559312Dec 8, 2000May 6, 2003Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6566526Nov 29, 2000May 20, 2003Merrell Pharmaceuticals Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6673933Mar 22, 2002Jan 6, 2004Aventis Pharmaceutical Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6683094Jun 12, 2002Jan 27, 2004Aventis Pharmaceuticals Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6689898Mar 22, 2002Feb 10, 2004Aventis Pharmaceuticals Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6700012Mar 22, 2002Mar 2, 2004Aventis Pharmaceuticals Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6730791Mar 22, 2002May 4, 2004Aventis Pharmaceuticals Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6777555Feb 12, 2003Aug 17, 2004Merrell Pharmaceuticals, Inc.Intermediates useful for the preparation of antihistaminic piperidine derivatives
US6797826Sep 4, 2002Sep 28, 2004Amr Technology, Inc.Piperidine derivatives and process for their production
US6919458Aug 5, 2002Jul 19, 2005Amr Technology, Inc.Process for production of piperidine derivatives
US6930197Mar 22, 2002Aug 16, 2005Aventis Pharmaceuticals Inc.Antihistaminic piperidine derivatives and intermediates for the preparation thereof
US6974872Aug 5, 2002Dec 13, 2005Amr Technology, Inc.Process for production of piperidine derivatives
US7022880Aug 13, 2004Apr 4, 2006Amr Technology , Inc.Piperidine derivatives and process for their production
US7238834Oct 14, 2005Jul 3, 2007Amr Technology, Inc.Piperidine derivatives and process for their production
US7390906Jun 19, 2006Jun 24, 2008Amr Technology, Inc.Piperidine derivatives and process for their production
US7560561May 6, 2005Jul 14, 2009Albany Molecular Research, Inc.Process for production of piperidine derivatives
US7678915Sep 15, 2006Mar 16, 2010Albany Molecular Research, Inc.Process for production of piperidine derivatives
US8022220Jun 11, 2009Sep 20, 2011Albany Molecular Research, Inc.Process for production of piperidine derivatives
US8476445Jan 13, 2010Jul 2, 2013Albany Molecular Research, Inc.Process for production of piperidine derivatives
DE2826437A1 *Jun 14, 1978Jan 3, 1980Schering Ag4-Cycloalkyl:methyl-phenyl-acetic acid derivs. - useful as antiinflammatories e.g. for treating arthritis
Classifications
U.S. Classification514/570, 568/329, 544/161, 562/460, 568/313, 568/316, 558/405, 560/52, 568/323, 568/330, 514/545
International ClassificationC07C49/813, C07C63/33, C07C69/95, C07C59/84, C07C59/86
Cooperative ClassificationC07C255/00, C07C45/004, C07C45/46, C07C45/63, C07C59/86, C07C59/84
European ClassificationC07C255/00, C07C45/00G, C07C45/63, C07C45/46, C07C59/84, C07C59/86